Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Starpharma Holdings Provides an Update on Sale of VIRALEZE Antiviral Nasal Spray

11 Jun 2021  |  14:44:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: VIRALEZE antiviral nasal spray registered for sale in India

Starpharma Holdings provided an update stating that the company had received confirmation that VIRALEZE antiviral nasal spray had been registered for sale nationally in India via the Central Drugs Standard Control Organisation (CDSCO), which is part of the Indian Ministry of Health and Family Welfare. The company advised that VIRALEZE is an easy-to-use antiviral nasal spray, which can be stored at room temperature and does not require cold storage or specialised transportation. The company also stated that it is in progressing discussions for B2B sales with a number of companies in India.

Please click here for full details

See more ASX300 News Announcements